Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has shared an update.
Simcere Pharmaceutical Group Limited announced a placing and top-up subscription agreement involving the sale of 121,000,000 existing shares and the issuance of an equivalent number of new shares under a general mandate. The transaction, coordinated by Morgan Stanley Asia Limited, is set at a placing price of HK$12.95 per share, representing a discount to recent trading prices. The gross proceeds are estimated at approximately HK$1,567.0 million, with net proceeds intended for specific applications. This strategic move aims to strengthen the company’s financial position and enhance its market presence, although it remains subject to certain conditions and may not proceed to completion.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating in the pharmaceutical industry. The company focuses on the development, production, and sale of pharmaceutical products.
Average Trading Volume: 21,755,235
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.94B
For detailed information about 2096 stock, go to TipRanks’ Stock Analysis page.